Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS)

Clinical and Experimental Immunology

Volumn 177, Issue 3, 2014, Pages 720-731

  Haverkamp, M H ^a,b   van de Vosse, E ^a   Goldbach Mansky, R ^b   Holland, S M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anakinra; CAPS; Cytokine; NOMID

Indexed keywords

CRYOPYRIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG DOSE ESCALATION; GENE MUTATION; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UPREGULATION;

ANAKINRA; CAPS; CYTOKINE; NOMID;

ADOLESCENT; ADULT; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; CYTOKINES; HUMANS; INFANT; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84904750134     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12361     Document Type: Article

References (35)

1. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID-CINCA. Curr Rheumatol Rep 2011; 13:123-131.
2. Gattorno M, Tassi S, Carta S etal. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56:3138-3148.
3. Henderson C, Goldbach-Mansky R. Monogenic IL-1 mediated autoinflammatory and immuynodeficiency symdromes: finding the right balance in response to danger signals. Clin Immunol 2010; 135:210-222.
4. ®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), 2011. Available at: http://omim.org/ (accessed 1 May 2012).
5. Aksentijevich I, Putnam CD, Remmers EF, Mueller JL, Le J, Kolodner RD. The clinical continuum of cryopyrinopathies. Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56:1273-1285.
6. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutations of a new gene encoding a putative purin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-305.
7. Touitou, I. Infevers: an online database for autoinflammatory mutations. 2012. http://fmf.igh.cnrs.fr/ISSAID/infevers/index.php (accessed 1 May 2012).
8. Tanaka N, Izawa K, Saito MH etal. High incidence of NLRP3 somatic mosaicism in chronic infantile neurological cutaneous and articular syndrome patients: results of an international multicenter collaborative study. Arthitis Rheum 2011; 63:3625-3632.
9. Shaw PJ, McDermott MF, Kanneganti T-D. Inflammasomes and autoimmunity. Trends Mol Med 2011; 17:57-64.
10. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720-3732.
11. Goldbach-Mansky R, Dailey NJ, Canna SW etal. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355:581-592.
12. Holland SM, Dorman SE, Kwon A etal. Abnormal regulation of interferon-γ, interleukin-12 and tumor necrosis factor-α in human interferon-γ receptor 1 deficiency. J Infect Dis 1998; 178:1095-1104.
13. Aróstegui JI, Aldea A, Modesto C etal. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004; 50:4045-4050.
14. Janssen R, Verhard E, Lankester A, ten Cate R, van Dissel JT. Enhanced interleukin-1β and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004; 50:3329-3333.
15. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-323.
16. Saito M, Fujisawa A, Nishikomori R etal. Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2005; 52:3579-3585.
17. Reddy S, Jia S, Geoffrey R etal. An autoinflammatory disease due to homozygous deletion of the ILRN locus. N Engl J Med 2009; 360:2438-2444.
18. Matsubayashi T, Sugiura H, Arai T, Oh-Ishi T, Inamo Y. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Pediatr 2006; 95:246-249.
19. Kuemmerle-Deschner JB, Lohse P, Koetter I etal. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther 2011; 13:R196.
20. Carta S, Tassi S, Delfino L etal. Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Ann Rheum Dis 2012; 71:1577-1581.
21. Aksentijevich I, Nowak M, Mallah M etal. De novo CIAS1 mutations, cytokine activation and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID). Arthritis Rheum 2002; 46:3340-3348.
22. Fujisawa A, Kambe N, Saito M etal. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood 2007; 109:2903-2911.
23. Saito M, Nishikomori R, Kambe N etal. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 2008; 111:2132-2141.
24. Hedrich CM, Bruck N, Paul D, Hahn G, Gahr M, Rösen-Wolff A. 'Mutation negative' familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. Rheumatol Int 2012; 32:2629-2636.
25. Lasiglie D, Traggiai E, Federici S etal. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLOS ONE 2011; 6:e20014.
26. Netea MG, Nold-Petry CA, Nold MF etal. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113:2324-2335.
27. Haverkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-γ-dependent signaling. Microbes Infect 2006; 8:1157-1166.
28. Newport MJ, Huxley CM, Huston S etal. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 355:1941-1949.
29. Dorman SE, Holland SM. Mutation in the signal transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101:2364-2369.
30. Dorman SE, Picard C, Lammas D etal. Clinical features of dominant and recessive interferon γ receptor 1 deficiencies. Lancet 2004; 364:2113-2121.
31. Rosenzweig SD, Dorman SE, Uzel G etal. A novel mutation in IFN-γ receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 2004; 173:4000-4008.
32. Noordzij JG, Hartwig NG, Verreck FAW etal. Two patients with complete defects in interferon gamma receptor-dependent signaling. J Clin Immunol 2007; 27:490-496.
33. Sologuren I, Boisson-Dupuis S, Pestano J etal. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet 2011; 20:1509-1523.
34. Sibley CH, Plass N, Snow J etal. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease (NOMID) treated with Anakinra. Arthritis Rheum 2012; 64:2375-2386.
35. Fox E, Jayaprakash N, Pham T-H, Goldbach-Mansky R. The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol 2010; 223:138-140.